Cyteir adds $80M to steer to Phase 2 with lead cancer drug, then maybe an IPO

Phase 2 testing of Cyteir’s lead cancer drug candidate later is slated to start later this year. The Series C round of funding includes crossover investors, whose involvement is a sign a biotech is preparing for an IPO.